PULSE BIOSCIENCES, INC. (PLSE) 8-K Current Report: March 9, 2026
Filed: March 9, 2026
Health Care
Surgical & Medical Instruments & ApparatusPULSE BIOSCIENCES, INC. (PLSE) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
PULSE BIOSCIENCES, INC. 8-K Mar 9, 2026 Event Analysis
Item 8.01 · Other Events
- • 21-patient study showed avg 74% volume reduction in benign thyroid nodules at 15-22 month follow-up — strong durability signal
- • Zero nodule regrowth and zero serious adverse events through 22 months — clean long-term safety/efficacy profile
- • 100% cosmetic satisfaction, 95% overall satisfaction — patient-reported outcomes support commercial differentiation
- • Continued volume reduction from month 1 through month 22 — suggests ongoing therapeutic effect, not plateau
- • Data presented at NASIT 2026 by lead investigator — peer-reviewed forum adds credibility ahead of potential regulatory/commercial milestones
Other PULSE BIOSCIENCES, INC. 8-K Filings
Get deeper insights on PULSE BIOSCIENCES, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.